Evidence map›Paper›PMID 35638031›Full record

ArticleAnnals of medicine and surgery (2012)2022

Case report of a recurrent resected glucagonoma.

Ouadi Yacine, Feryel Letaief Ksontini, Ahmed Ben Mahmoud, Houcine Magherbi, Samir Fadhel Fterich, Montasser Kacem

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ouadi YacineDepartment of Surgery, A La Rabta, Tunis, Tunisia.
Feryel Letaief KsontiniFaculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.
Ahmed Ben MahmoudDepartment of Surgery, A La Rabta, Tunis, Tunisia.
Houcine MagherbiDepartment of Surgery, A La Rabta, Tunis, Tunisia.
Samir Fadhel FterichDepartment of Surgery, A La Rabta, Tunis, Tunisia.
Montasser KacemDepartment of Surgery, A La Rabta, Tunis, Tunisia.
Hôpital La Rabta · TNTunis El Manar University · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction and importance: Glucagonoma is a rare neuroendocrine tumor (NET). Most glucagonomas are in the tail or body of the pancreas and are diagnosed at a metastatic stage. We report a case of an early recurrence after surgical resection of a glucagonoma and its management. Case report: We present a case of a 44-year-old female patient with no medical and surgical history, operated on in May 2018 for pancreatic glucagonoma revealed by skin necrolytic migratory erythema. The patient was regularly monitored by clinical exams and CT scans. In December 2020 (31 months postoperatively), we noticed the recurrence of the cutaneous lesions.Admission laboratory measurements demonstrated hyperglycemia as well as elevated blood Glucagon levels. Explorations showed 3 retro-pancreatic lesions. Based on these findings, we concluded that it was a recurrence of her glucagonoma. The patient was operated on by median laparotomy We performed a warshow's procedure.Pathology confirmed the endocrine nature of the 3 nodules. We are currently 6 months behind the surgery. The examination is strictly normal with no recurrence of the skin lesions so far. Clinical discussion: Surgical resection on a recurrent glucagonoma is what is unique in our case as we haven't found any case in the literature to our knowledge.What is also unique about our case is both the local aspect of the recurrence and the multiplicity of the tumors observed as multiple nodules around the tail of the pancreas. These lesions were not metastatic lymph nodes as confirmed by pathology. Probably it was an effraction of the big tumor at enucleation. Conclusion: Due to its rareness, there is no clear consensus on the management of glucagonomas therefore we chose to write our case in order to further enrich the literature to achieve one-day guidelines for glucagonomas treatment.

Indexed as

Case reportGeneral surgeryGlucagonomaNeuroendocrine tumor

Identifiers

PMID35638031
PMCPMC9142409
OpenAlexW4226120481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.